Development asset linked to Servier Australia in public FDA and regional records. Molecular target: Sulfonylurea receptor 1, Kir6.2.
- Target
- Sulfonylurea receptor 1, Kir6.2
- Mechanism
- Sulfonylurea receptor 1, Kir6.2 blocker
pharma · Chronic Lymphocytic Leukaemia (CLL)
Servier Australia
Servier Laboratories (Aust.) Pty.
Servier Australia drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Melbourne, AU HQ
1954 Founded
11 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- Melbourne, AU
- Founded
- 1954
- Employees
- 11
- Programs
- 1
- Drugs
- 7
- Patents
- 0
Servier Australia pipeline
Portfolio lens on 7 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Servier Australia drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
ivabradine
Cardiovascular system (C01)US regulatory status: approved. Molecular target: Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4.
- Target
- Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4
- Mechanism
- Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker
-
ivosidenib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Isocitrate dehydrogenase [NADP] cytoplasmic.
- Target
- Isocitrate dehydrogenase [NADP] cytoplasmic
- Mechanism
- Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor
-
Development asset linked to Servier Australia in public FDA and regional records. Mechanism: Angiotensin-converting enzyme inhibitor.
- Mechanism
- Angiotensin-converting enzyme inhibitor
-
Development asset linked to Servier Australia in public FDA and regional records.
-
risperidone
Nervous system (N05)US regulatory status: approved. Molecular target: D(2) dopamine receptor.
- Target
- D(2) dopamine receptor
- Mechanism
- Serotonin 2c (5-HT2c) receptor antagonist
-
Development asset linked to Servier Australia in public FDA and regional records.